We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics. Compounds with 2S,5S stereochemistry at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogues. Furthermore, the attachment of substituents at the 4-position of the central N-phenyl group resulted in compounds with improved potency. Substitution with tert-butyl, as in compound 38 (ABT-267), provided compounds with low-picomolar EC50 values and superior pharmacokinetics. It was discovered that compound 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a. Compound 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clinical trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.
Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an HCV NS5A inhibitor. First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equivalent efficacy against HCV virus genotypes 1-6. In particular, these first generation NS5A inhibitors tend to select for viral drug resistance. Ombitasvir is a first generation HCV NS5A inhibitor included as a key component of Viekira Pak for the treatment of patients with HCV genotype 1 infection. Since the launch of next generation HCV treatments, functional cure for genotype 1-6 HCV infections has been achieved, as well as shortened treatment duration across a wider spectrum of genotypes. In this paper, we show how we have modified the anchor, linker, and end-cap architecture of our NS5A inhibitor design template to discover a next generation NS5A inhibitor pibrentasvir (ABT-530), which exhibits potent inhibition of the replication of wild-type genotype 1-6 HCV replicons, as well as improved activity against replicon variants demonstrating resistance against first generation NS5A inhibitors.
The ketoacid, 2-(4-diethylamino-2-hydroxybenzoyl)benzoic acid, prepared from N,N-diethyl-m-aminophenol and phthalic anhydride, was reacted with various substituted 3-[6-methoxybenzothiazol-2-yl]-4(3H)-quinazolinones in the presence of a dehydration condensing agent to afford novel spiro[isobenzofuran-1(3H),9?-xanthene]-3-ones. The benzothiazolyl quinazolinones were synthesized by reacting 2-amino-6-methoxybenzothiazole with various substituted benzoxazinones. All compounds were characterized by melting point determination, elemental analysis, infra- red spectroscopy NMR-spectroscopy and UV-visible sprectroscopy. All the fluoran compounds are colourless or nearly colourless and produce colour in the presence of acidic media.
New quinazolinone-substituted fluoran compounds were synthesized by reaction of keto acid, 2'-carboxy-2-hydroxy-4-N-pyrrolidinylbenzophenone with different quinazolinone derivatives in the presence of conc. sulphuric acid. All the synthesized fluoran compounds were characterized by spectroscopic methods (IR, 1 H-NMR and UV-visible spectroscopy) and elemental analysis. The fluoran compounds are colourless or nearly colourless and develop colour on contact with electron-accepting compounds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.